The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema

Paul Mitchell; Francesco Bandello; Ursula Schmidt-Erfurth; Gabriele E. Lang; Pascale Massin; Reinier O. Schlingemann; Florian Sutter; Christian Simader; Gabriela Burian; Ortrud Gerstner; Andreas Weichselberger

doi:10.1016/j.ophtha.2011.01.031

The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema

Paul Mitchell, Francesco Bandello, Ursula Schmidt-Erfurth, Gabriele E. Lang, Pascale Massin, Reinier O. Schlingemann, Florian Sutter, Christian Simader, Gabriela Burian, Ortrud Gerstner, Andreas Weichselberger

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article

Abstract

Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. Participants: We included 345 patients aged 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P

Original language	English
Pages (from-to)	615-625
Number of pages	11
Journal	Ophthalmology
Volume	118
Issue number	4
DOIs	https://doi.org/10.1016/j.ophtha.2011.01.031
Publication status	Published - Apr 2011

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.ophtha.2011.01.031

Fingerprint Dive into the research topics of 'The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema'. Together they form a unique fingerprint.

Cite this

Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., & Weichselberger, A. (2011). The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology, 118(4), 615-625. https://doi.org/10.1016/j.ophtha.2011.01.031

The RESTORE study : Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. / Mitchell, Paul; Bandello, Francesco; Schmidt-Erfurth, Ursula; Lang, Gabriele E.; Massin, Pascale; Schlingemann, Reinier O.; Sutter, Florian; Simader, Christian; Burian, Gabriela; Gerstner, Ortrud; Weichselberger, Andreas.

In: Ophthalmology, Vol. 118, No. 4, 04.2011, p. 615-625.

Research output: Contribution to journal › Article

Mitchell, Paul ; Bandello, Francesco ; Schmidt-Erfurth, Ursula ; Lang, Gabriele E. ; Massin, Pascale ; Schlingemann, Reinier O. ; Sutter, Florian ; Simader, Christian ; Burian, Gabriela ; Gerstner, Ortrud ; Weichselberger, Andreas. / The RESTORE study : Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. In: Ophthalmology. 2011 ; Vol. 118, No. 4. pp. 615-625.

@article{74a3cdb7164b434bb711cb34ed60782f,

title = "The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema",

abstract = "Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. Participants: We included 345 patients aged 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P",

author = "Paul Mitchell and Francesco Bandello and Ursula Schmidt-Erfurth and Lang, {Gabriele E.} and Pascale Massin and Schlingemann, {Reinier O.} and Florian Sutter and Christian Simader and Gabriela Burian and Ortrud Gerstner and Andreas Weichselberger",

year = "2011",

month = apr,

doi = "10.1016/j.ophtha.2011.01.031",

language = "English",

volume = "118",

pages = "615--625",

journal = "Ophthalmology",

issn = "0161-6420",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - The RESTORE study

T2 - Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema

AU - Mitchell, Paul

AU - Bandello, Francesco

AU - Schmidt-Erfurth, Ursula

AU - Lang, Gabriele E.

AU - Massin, Pascale

AU - Schlingemann, Reinier O.

AU - Sutter, Florian

AU - Simader, Christian

AU - Burian, Gabriela

AU - Gerstner, Ortrud

AU - Weichselberger, Andreas

PY - 2011/4

Y1 - 2011/4

N2 - Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. Participants: We included 345 patients aged 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P

AB - Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. Participants: We included 345 patients aged 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P

UR - http://www.scopus.com/inward/record.url?scp=79953311138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953311138&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2011.01.031

DO - 10.1016/j.ophtha.2011.01.031

M3 - Article

C2 - 21459215

AN - SCOPUS:79953311138

VL - 118

SP - 615

EP - 625

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 4

ER -